Imperial College London

NPL, Imperial College London launch virtual lab

Friday, November 10, 2017

NPL, the UK’s National Measurement Institute (NMI), and SynbiCITE at Imperial College London, have announced the establishment of a new £7 million virtual lab to underpin their joint Centre for Engineering Biology, Metrology and Standards to help the UK synthetic biology industry improve the manufacturing and adoption of new products – in partnership with LGC and NIBSC.

[Read More]

Luxcel Biosciences, Axiogenesis, BMG LABTECH to develop cell metabolism analysis platform

Thursday, February 16, 2017

Three European technology SMEs, together with two research institutions, Oxford University and Imperial College London, have been awarded €2.5 million funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development. 

[Read More]

Protectimmun partners with J&J, Imperial College

Wednesday, September 30, 2015

Protectimmun, a Germany-based biopharmaceutical R&D company, has entered into a research funding agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and Imperial College London. The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research conducted at Imperial College by professor Clare Lloyd with one of Protectimmun’s lead candidates in a proof-of-concept disease model of allergic asthma developed by Lloyd.

[Read More]

MRC, GSK, five U.K. universities collaborate on difficult disease areas

Wednesday, July 15, 2015

Medical Research Council (MRC), GlaxoSmithKline and five U.K. universities are collaborating on difficult disease areas. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.

[Read More]

Heptares expands board of directors

Thursday, January 8, 2015

Heptares Therapeutics, a clinical-stage GPCR structure-guided drug discovery and development company, has appointed Atul Pande and Roberto Solari to its board of directors. Pande and Solari bring significant industry experience in the discovery and validation of drug targets and the subsequent development of novel medicines.

[Read More]

International Progressive MS Alliance awards $28.4M in research grants

Tuesday, September 16, 2014

The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries, with the goal of removing barriers to developing treatments for progressive multiple sclerosis (MS). The alliance is a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis that have so far eluded the scientific community.

[Read More]

Medical Research Council launches U.K. Dementias Research Platform

Thursday, June 19, 2014

The Medical Research Council (MRC) has launched the U.K. Dementias Research Platform (UKDP), a $27.2 million public-private partnership set up to speed up research into dementias. The collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

[Read More]